Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for liver fat reduction in adults with non-alcoholic fatty liver disease and type 2 diabetes
IRCT20241117063753N1Phase 3Completed
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Reduction in liver fat, Improvement in liver enzymes and 2 more. Started Dec 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20241117063753N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241117063753N1.